Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) CFO Sells 4,769 Shares of Stock

November 5, 2026 by InsiderTrades.com

Key Points

CFO Hans van Houte sold 4,769 shares for about $74,539 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 10.04% to 42,745 shares.
Sanofi is ending development of SAR448272, a Phase 1 STAT6 degrader licensed from Nurix, a setback for the company’s partnered pipeline.
Analyst sentiment remains broadly positive: Nurix has a “Moderate Buy” consensus and a $34.43 average price target, although Wells Fargo cut its target to $20 while retaining an “overweight” rating.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Hans van Houte sold 4,769 shares of the firm's stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $15.63, for a total transaction of $74,539.47. Following the sale, the chief financial officer owned 42,745 shares in the company, valued at approximately $668,104.35. This trade represents a 10.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):

On Friday, October 30th, Hans van Houte sold 2,834 shares of Nurix Therapeutics stock. The stock was sold at an average price of $26.28, for a total transaction of $74,477.52.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $15.95 on Thursday. The stock has a fifty day moving average of $24.73 and a two-hundred day moving average of $20.25. The company has a market capitalization of $1.74 billion, a PE ratio of 6.90 and a beta of 1.80. Nurix Therapeutics, Inc. has a fifty-two week low of $11.67 and a fifty-two week high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The company had revenue of $673.06 million for the quarter, compared to analyst estimates of $24.35 million. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current fiscal year.

Nurix Therapeutics News Summary

Here are the key news stories impacting Nurix Therapeutics this week:

Neutral Sentiment: Wells Fargo lowered its price target for NRIX from $25 to $20 but maintained an “overweight” rating, signaling continued optimism despite reduced expectations. Wells Fargo price target
Neutral Sentiment: CFO Hans van Houte sold 4,769 shares under a pre-arranged Rule 10b5-1 plan. The planned sale may draw attention, though it is less indicative of a new view on the company than an unplanned transaction. SEC filing
Negative Sentiment: Sanofi is discontinuing its Phase 1 trial and terminating the program for SAR448272, an oral STAT6 degrader licensed from Nurix. Losing a partnered clinical program weakens the pipeline’s potential value and appears to be the main catalyst behind the selloff. BioSpace reported the decision was not related to the drug’s target, which may help distinguish the setback from a broader issue with STAT6. Nurix announcement BioSpace report

Analysts Set New Price Targets

NRIX has been the subject of several analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $34.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, October 13th. Oppenheimer raised their price target on Nurix Therapeutics from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 13th. HC Wainwright lifted their price target on Nurix Therapeutics from $34.00 to $36.00 and gave the company a "buy" rating in a report on Friday, October 16th. Mizuho lifted their price target on Nurix Therapeutics from $30.00 to $34.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Finally, Wells Fargo & Company dropped their price objective on shares of Nurix Therapeutics from $25.00 to $20.00 and set an "overweight" rating for the company in a research note on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $34.43.

Check Out Our Latest Analysis on Nurix Therapeutics

Hedge Funds Weigh In On Nurix Therapeutics

A number of large investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC boosted its holdings in shares of Nurix Therapeutics by 7.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 14,916 shares of the company's stock valued at $348,000 after purchasing an additional 1,072 shares during the last quarter. AlphaCentric Advisors LLC increased its holdings in shares of Nurix Therapeutics by 4.5% during the 3rd quarter. AlphaCentric Advisors LLC now owns 27,006 shares of the company's stock worth $640,000 after buying an additional 1,161 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Nurix Therapeutics during the 3rd quarter worth $126,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 15.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,936 shares of the company's stock worth $448,000 after buying an additional 2,479 shares during the last quarter. Finally, Sterling Capital Management LLC raised its position in shares of Nurix Therapeutics by 310.4% in the 3rd quarter. Sterling Capital Management LLC now owns 2,885 shares of the company's stock worth $68,000 after buying an additional 2,182 shares during the period.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company's pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton's tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.